Comparing Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Absci (NASDAQ:ABSI)

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Free Report) and Absci (NASDAQ:ABSI – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Earnings and Valuation

This table compares Arrowhead Pharmaceuticals and Absci”s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arrowhead Pharmaceuticals $669.50 million 9.72 -$724.21 million ($5.11) -9.04
Absci $1.49 million 908.16 -$115.18 million ($0.79) -9.96

Absci has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Absci is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Arrowhead Pharmaceuticals and Absci’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Arrowhead Pharmaceuticals -160.64% -172.62% -37.51%
Absci -8,451.31% -61.60% -55.30%

Insider and Institutional Ownership

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 52.0% of Absci shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 10.5% of Absci shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Arrowhead Pharmaceuticals and Absci, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arrowhead Pharmaceuticals 1 3 10 1 2.73
Absci 1 0 11 0 2.83

Arrowhead Pharmaceuticals presently has a consensus price target of $98.93, suggesting a potential upside of 114.06%. Absci has a consensus price target of $14.90, suggesting a potential upside of 89.35%. Given Arrowhead Pharmaceuticals’ higher probable upside, research analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Absci.

Volatility & Risk

Arrowhead Pharmaceuticals has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500. Comparatively, Absci has a beta of 2.22, suggesting that its share price is 122% more volatile than the S&P 500.

Summary

Absci beats Arrowhead Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About Arrowhead Pharmaceuticals

(Get Free Report)

Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.

About Absci

(Get Free Report)

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.